Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

P2Y12 receptor inhibitor resistance and coronary artery disease: a bench to bedside primer for cardiovascular specialists.

Current opinion in cardiology - 1 Sept 2017

So Derek Y F, Bagai Akshay, Tran Uyen, Verma Subodh, Mehta Shamir R

Abstract excerpt

PURPOSE OF REVIEW: Platelet P2Y12 receptor inhibitors are routinely prescribed for patients after acute coronary syndromes and percutaneous coronary interventions. Patients may have underresponsiveness (or resistance) to these drugs and in particular to clopidogrel, the most often used type. This review aims to focus on the concept of P2Y12 receptor inhibitor resistance and discuss incidence, mechanisms, novel...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Platelets
Share to Coronary Artery Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance

Share to Platelet Aggregation

Share to Platelet Aggregation Inhibitors

Share to Platelet Function Tests

Share to Purinergic P2Y Receptor Antagonists

Share to Ticlopidine

Source

Identifiers

PMID: 28661903
DOI: 10.1097/HCO.0000000000000440

Genes

HPR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

P2Y12 receptor inhibitor resistance and coronary artery disease: a bench to bedside primer for cardiovascular specialists.PMID 28661903Read ↗

Response variability to P2Y12 receptor inhibitors: expectations and reality.Semantic proximity Read ↗

Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance.Semantic proximity Read ↗

Pharmacogenetics of P2Y 12 receptor inhibitorsSemantic proximity Read ↗

Pharmacogenetics of Antiplatelet Therapy.Semantic proximity Read ↗

High platelet reactivity and clinical outcome - fact and fiction.Semantic proximity Read ↗

Identifying responsiveness to oral P2Y12 receptor blockers: platelet function assays and genetic tests.Semantic proximity Read ↗

Clopidogrel Resistance: Pharmacokinetic or Pharmacogenetic?Semantic proximity Read ↗

Platelet function and antiplatelet therapy in cardiovascular disease: implications of genetic polymorphisms.Semantic proximity Read ↗

Review of aspirin and clopidogrel resistance in peripheral arterial disease.Semantic proximity Read ↗

The Role of Genetic Polymorphism and Other Factors on Clopidogrel Resistance (CR) in an Asian Population with Coronary Heart Disease (CHD).Semantic proximity Read ↗

Can CYP2C19 genotyping improve antiplatelet therapy efficacy in real-life practice? Recent advances.Semantic proximity Read ↗

Genetic Determinants of P2Y12 Inhibitors and Clinical Implications.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.